Beam Therapeutics Inc. Cash and Restricted Cash
Beam Therapeutics Inc. (BEAM) had Cash and Restricted Cash of $226.54 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $226.54M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $294.98M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $301.62M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $274.62M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $226.54M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $294.98M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $301.62M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $274.62M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $288.76M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $534.52M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $290.11M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $236.75M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $298.92M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $294.30M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $444.61M 10-K · filed 2026-02-24 |
| 2023-09-30 | $177.73M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $240.97M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $259.57M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $245.52M 10-K · filed 2026-02-24 |
| 2022-09-30 | $169.26M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $278.37M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $309.57M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $572.74M 10-K · filed 2025-02-25 |
| 2021-09-30 | $626.86M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $226.85M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $112.08M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $177.01M 10-K · filed 2024-02-27 |
| 2020-09-30 | $152.74M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $138.63M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $139.38M 10-Q · filed 2021-05-11 |
| 2019-12-31 | $50.55M 10-K · filed 2023-02-28 |
| 2019-09-30 | $51.09M 10-Q · filed 2020-11-10 |
| 2019-06-30 | $51.18M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $157.63M 10-Q · filed 2020-05-12 |
| 2018-12-31 | $147.94M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |